`INTERNATIONAL TRADE COMMISSION
`
`
`
`
`
`
`
`___________________________________
`
`In the Matter of: ) Investigation No.
`
`CERTAIN PRE-FILLED SYRINGES FOR ) 337-TA-1207
`
`INTRAVITREAL INJECTION AND )
`
`COMPONENTS THEREOF )
`
`___________________________________
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pages:
`
`Place:
`
`Date:
`
`1 through 276
`Washington, D.C.
`December 10, 2020
`
`
`HERITAGE REPORTING CORPORATION
`Official Reporters
`1220 L Street, N.W., Suite 206
`Washington, D.C. 20005
`(202) 628-4888
`www.hrccourtreporters.com
`
`
`
`
`
`Novartis Exhibit 2049.001
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
`
` 1
`
`
` 1 UNITED STATES INTERNATIONAL TRADE COMMISSION
`
` 2 Washington, D.C.
`
` 3 BEFORE THE HONORABLE CLARK S. CHENEY
`
` 4 Administrative Law Judge
`
` 5 ___________________________________
`
` 6 In the Matter of: ) Investigation No.
`
` 7 CERTAIN PRE-FILLED SYRINGES FOR ) 337-TA-1207
`
` 8 INTRAVITREAL INJECTION AND )
`
` 9 COMPONENTS THEREOF )
`
` 10 ___________________________________
`
` 11
`
` 12 Remote Hearing
`
` 13
`
` 14 Thursday, December 10, 2020
`
` 15
`
` 16 MARKMAN HEARING
`
` 17
`
` 18 The Hearing commenced remotely, pursuant to the
`
` 19 notice of the Judge, at 9:02 a.m. EST.
`
` 20
`
` 21
`
` 22
`
` 23
`
` 24
`
` 25 Reported by: Marjorie Peters, FAPR, RMR, CRR
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.002
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
` 2
`
`
` 1 APPEARANCES:
`
` 2
`
` 3 ** All parties appearing remotely **
`
` 4
`
` 5 FOR COMPLAINANTS NOVARTIS PHARMA AG, NOVARTIS
`
` 6 PHARMACEUTICALS CORPORATION, NOVARTIS TECHNOLOGYLLC:
`
` 7
`
` 8 ELIZABETH J. HOLLAND, ESQ.
`
` 9 DANIEL P. MARGOLIS, Ph.D., ESQ.
`
` 10 MOLLY GRAMMEL, ESQ.
`
` 11 Goodwin Procter LLP
`
` 12 The New York Times Building
`
` 13 620 Eighth Avenue
`
` 14 New York, New York 10018
`
` 15 212-813-8800
`
` 16
`
` 17 MARK G. DAVIS, ESQ.
`
` 18 WILLIAM JAMES, ESQ.
`
` 19 PATRICK J. McCARTHY, ESQ.
`
` 20 MYOMI T. COAD, ESQ.
`
` 21 Goodwin Procter LLP
`
` 22 1900 N Street, N.W.
`
` 23 Washington, D.C. 20036
`
` 24 202-346-4000
`
` 25
`
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.003
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
` 3
`
`
` 1 APPEARANCES: (CONTINUED)
`
` 2
`
` 3 FOR RESPONDENT REGENERON PHARMACEUTICALS, INC.:
`
` 4 ANISH R. DESAI, ESQ.
`
` 5 ELIZABETH STOTLAND WEISWASSER, ESQ.
`
` 6 NATALIE C. KENNEDY, ESQ.
`
` 7 ANDREW P. GESIOR, ESQ.
`
` 8 Weil, Gotshal & Manges LLP
`
` 9 767 Fifth Avenue
`
` 10 New York, New York 10153
`
` 11 212-310-8000
`
` 12
`
` 13 BRIAN E. FERGUSON, ESQ.
`
` 14 CHRISTOPHER PEPE, ESQ.
`
` 15 ROBERT T. VLASIS, ESQ.
`
` 16 Weil, Gotshal & Manges LLP
`
` 17 2001 M Street, N.W., Suite 600
`
` 18 Washington, D.C. 20036
`
` 19 202-682-7000
`
` 20
`
` 21
`
` 22
`
` 23
`
` 24
`
` 25
`
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.004
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
` 4
`
`
` 1 APPEARANCES (Continued):
`
` 2
`
` 3 FOR THE OFFICE OF UNFAIR IMPORT INVESTIGATIONS:
`
` 4 W. PETER GUARNIERI, ESQ.
`
` 5 ANNE GOALWIN, ESQ.
`
` 6 U.S. International Trade Commission
`
` 7 500 E Street, S.W.
`
` 8 Washington, D.C. 20436
`
` 9 202-205-2221
`
` 10
`
` 11
`
` 12
`
` 13
`
` 14
`
` 15
`
` 16
`
` 17
`
` 18
`
` 19
`
` 20
`
` 21
`
` 22
`
` 23
`
` 24
`
` 25
`
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.005
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
` 5
`
`
` 1 P R O C E E D I N G S
`
` 2 (9:03 a.m.)
`
` 3 JUDGE CHENEY: We're on the record now in
`
` 4 Investigation No. 337-TA-1207. This is Certain Pre-Filled
`
` 5 Syringes For Intravitreal Injection and Components Thereof.
`
` 6 Good morning, everyone. My name is
`
` 7 Clark Cheney. I'm the Administrative Law Judge assigned to
`
` 8 collect and gather evidence and issue an initial
`
` 9 determination in this case.
`
` 10 We are gathered today for a claim construction
`
` 11 hearing. Before we get too deep into that hearing, let's
`
` 12 go around and have the parties enter their appearances,
`
` 13 beginning with the counsel for the Complainant,
`
` 14 Ms. Holland.
`
` 15 MS. HOLLAND: Thank you, Your Honor.
`
` 16 Elizabeth Holland of Goodwin Procter for
`
` 17 Complainant Novartis.
`
` 18 With me from Goodwin Procter and the people who
`
` 19 may speak on the record are William James, Daniel Margolis
`
` 20 and Mark Davis.
`
` 21 JUDGE CHENEY: Welcome, all.
`
` 22 MS. HOLLAND: We also have client
`
` 23 representatives from Novartis, Your Honor. I don't know if
`
` 24 you want them specifically identified.
`
` 25 JUDGE CHENEY: I'd be delighted to be introduced
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.006
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
` 6
`
`
` 1 to them.
`
` 2 MS. HOLLAND: Okay.
`
` 3 I'm going to look at my screen to see if I --
`
` 4 make sure I catch everybody.
`
` 5 So we have Mr. Peter Waibel. We have Ms. Cindy
`
` 6 Lopez. Let's see as I go down here. Ms. Paki Banky,
`
` 7 Mr. John Hutchinson, and -- I'm looking at the Hollywood
`
` 8 Squares here trying to make sure I got everybody.
`
` 9 I think that's everybody, Your Honor.
`
` 10 JUDGE CHENEY: Thank you. Welcome to all of
`
` 11 you. Thank you for being with us in this hearing today.
`
` 12 Counsel for the respondents, Mr. Desai.
`
` 13 MR. DESAI: For Respondent, Regeneron, I will be
`
` 14 presenting along with Elizabeth Weiswasser. We'll be
`
` 15 switching seats, which is why you don't see her on the
`
` 16 video right now.
`
` 17 Also on the line who may be speaking at some
`
` 18 point today is Chris Pepe, and then also we have -- from
`
` 19 Regeneron, we have Larry Coury, Petra Scamborova, and I
`
` 20 believe also Lynda Nguyen and our expert witness,
`
` 21 Dr. Rexler.
`
` 22 JUDGE CHENEY: Welcome, all. I appreciate the
`
` 23 client representatives that are joining us today.
`
` 24 I understand this is an important dispute
`
` 25 between your companies, and it -- I appreciate the interest
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.007
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
` 7
`
`
` 1 that you've shown in our proceedings.
`
` 2 Counsel for the Commission Investigative Staff,
`
` 3 please enter your appearance.
`
` 4 MR. GUARNIERI: Good morning, Your Honor.
`
` 5 Pete Guarnieri on behalf of the Office of Unfair
`
` 6 Import Investigations at the ITC. I'll be doing the
`
` 7 presenting and speaking today, but I'm also joined by my
`
` 8 colleague, Ms. Anne Goalwin.
`
` 9 JUDGE CHENEY: Welcome to you both.
`
` 10 I will note that today's proceeding is on the
`
` 11 public record. Although we're conducting the proceeding
`
` 12 over a video platform, we have members of the public that
`
` 13 are joining us, that are not signed on to the protective
`
` 14 order in this investigation.
`
` 15 So please conduct yourselves accordingly.
`
` 16 Now, let's talk a little bit about the format of
`
` 17 today's proceeding.
`
` 18 I received a joint submission from the parties
`
` 19 outlining an agreed format for today's proceeding. Under
`
` 20 that agreement, we will begin with opening statements.
`
` 21 Then we'll have the presentation of evidence and
`
` 22 witnesses, with the Complainant going first, followed by
`
` 23 the Respondent and then the Staff. And then there will be
`
` 24 closing statements.
`
` 25 I will let you all know that during the
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.008
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
` 269
`
`
` 1 But it also is informative about the standard
`
` 2 that the Federal Circuit and other courts are using in
`
` 3 dealing with this.
`
` 4 I was very interested in Dr. Sawyer's testimony
`
` 5 that we know that the next rung is a boundary. That seems
`
` 6 to cut against indefiniteness, and sounded very much like
`
` 7 the Guangdong case where even though we can't say where it
`
` 8 is in between, we know there is something beyond which the
`
` 9 claim does not -- is not covered.
`
` 10 Those are my initial thoughts.
`
` 11 Having heard that, does someone want to try to
`
` 12 convince me that I'm mistaken in a post-hearing brief?
`
` 13 I'm totally fine with that. I just -- I just
`
` 14 want you all to hear where I'm thinking -- how I'm thinking
`
` 15 about this case so that you can figure out how to use your
`
` 16 resources.
`
` 17 To the extent that anyone was hoping that this
`
` 18 case was not going to go to trial, this case is going to go
`
` 19 to trial.
`
` 20 Let me start with you, Ms. Holland.
`
` 21 Any thoughts?
`
` 22 MS. HOLLAND: No, Your Honor. On behalf of
`
` 23 Novartis, we don't -- given what Your Honor just said, we
`
` 24 don't see the need for any post-hearing briefing.
`
` 25 JUDGE CHENEY: Okay. Mr. Desai, I understand
`
`
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.009
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`
`
` 276
`
`
` 1 CERTIFICATE OF REPORTER
`
` 2 TITLE: CERTAIN PRE-FILLED SYRINGES FOR INTRAVITREAL
`
` 3 INJECTION AND COMPONENTS THEREOF
`
` 4 INVESTIGATION NO: 337-TA-1207
`
` 5 HEARING DATE: December 10, 2020
`
` 6 LOCATION: Washington, D.C. - Remote
`
` 7 NATURE OF HEARING: Markman Hearing
`
` 8 I hereby certify that the foregoing/attached
` transcript is a true, correct and complete record of the
` 9 above-referenced proceedings of the U.S. International
` Trade Commission.
` 10 Date: December 11, 2020
`
` 11 SIGNED:
`
` 12 Signature of the Contractor of the
` Authorized Contractor's Representative
` 13 1220 L Street, N.W, Suite 206
` Washington, D.C. 20005
` 14
` I hereby certify that I am not the Court Reporter
` 15 and that I have proofread the above-referenced transcript
` of the proceedings of the U.S. International Trade
` 16 Commission, against the aforementioned Court Reporter's
` notes and recordings, for accuracy in transcription in the
` 17 spelling, hyphenation, punctuation and speaker
` identification and did not make any changes of a
` 18 substantive nature. The foregoing/attached transcript is a
` true, correct and complete transcription of the
` 19 proceedings.
`
` 20 SIGNED:
` Signature of Proofreader
` 21
` I hereby certify that I reported the above-referenced
` 22 proceedings of the U.S. International Trade Commission and
` caused to be prepared from my tapes and notes of the
` 23 proceedings a true, correct and complete verbatim recording
` of the proceedings.
` 24
` SIGNED:
` 25 Signature of the Court Reporter
`
`
`
`
`Heritage Reporting Corporation
`(202) 628-4888
`
`Novartis Exhibit 2049.010
`Regeneron v. Novartis, IPR2020-01317
`
`